Adavosertib,Afatinib Dimaleate,Binimetinib,Capivasertib,Copanlisib,Copanlisib Hydrochloride,Crizotinib,Dabrafenib,Dabrafenib Mesylate,Defactinib,Defactinib Hydrochloride,Erdafitinib,Ipatasertib,Larotrectinib,Larotrectinib Sulfate,Nivolumab,Osimertinib,Pertuzumab,Relatlimab,Sapanisertib,Taselisib,Trametinib,Trastuzumab,Trastuzumab Emtansine,Ulixertinib,Vismodegib
Astrazeneca,Boehringer Ingelheim,ono pharmacueticals,pierre fabre,Otsuka,AstraZeneca,Bayer,Pfizer,Novartis,verastem,janssen,Roche,Bms,calithera,biomed valley discoveries
['nci-match']
schalper #aacr23 dna/rna alternation using oncomine v3 (used with nci-match). 161 genes: orthog validation for spec included sanger, cobas qpcr, and ngs. sens. was done via dilution series, showed 1% tumor fraction.
Business development, marketing and sales professional in the life sciences, cancer diagnostics, and genomics fields. Blog: https://t.co/IeMzCogxlt. Opinions are my own.